TRVN — Trevena Share Price
0.000.00%
Last trade - 00:00- $6.99m
- $4.84m
- $3.13m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.24 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -106.77% | ||
| Return on Equity | -1014.58% | ||
| Operating Margin | -1129.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.03 | 3.07 | 0.57 | -0.42 | 3.13 | n/a | 8.95 | -11.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).
Directors
- Leon Moulder NEC (63)
- Carrie Bourdow PRE (58)
- Barry Shin CFO (49)
- Mark Demitrack SVP (63)
- Robert Yoder SVP (55)
- Scott Braunstein IND
- Michael Dougherty IND (63)
- Marvin Johnson IND (58)
- Jake Nunn IND (45)
- Anne Phillips IND (67)
- Barbara Yanni IND (67)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 9th, 2007
- Public Since
- January 31st, 2014
- No. of Shareholders
- 5
- No. of Employees
- 23
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 18,321,010
- Address
- 955 Chesterbrook Boulevard, Suite 110, CHESTERBROOK, 19087
- Web
- https://www.trevena.com/
- Phone
- +1 6103548840
- Contact
- Dan Ferry
- Auditors
- Ernst & Young LLP
Upcoming Events for TRVN
Q1 2024 Trevena Inc Earnings Release
Trevena Inc Annual Shareholders Meeting
Q2 2024 Trevena Inc Earnings Release
Similar to TRVN
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Trevena share price?
As of Today at 19:22 UTC, shares in Trevena are trading at $0.38. This share price information is delayed by 15 minutes.
How has the Trevena share price performed this year?
Shares in Trevena last closed at $0.38 and the price had moved by -50.85% over the past 365 days. In terms of relative price strength the Trevena share price has underperformed the S&P500 Index by -60.31% over the past year.
What are the analyst and broker recommendations for Trevena?
The overall consensus recommendation for Trevena is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Trevena dividend yield?
Trevena does not currently pay a dividend.
Does Trevena pay a dividend?
Trevena does not currently pay a dividend.
When does Trevena next pay dividends?
Trevena does not currently pay a dividend.
How do I buy Trevena shares?
To buy shares in Trevena you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Trevena?
As of the previous close price of $0.38, shares in Trevena had a market capitalisation of $6.99m.
Where are Trevena shares listed?
Here are the trading details for Trevena:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: TRVN
What kind of share is Trevena?
Based on an overall assessment of its quality, value and momentum Trevena is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Trevena share price forecast for 2024?
The analyst consensus target price for shares in Trevena is $6.00. That is 1473.15% above the last closing price of $0.38.
Analysts covering Trevena currently have a consensus Earnings Per Share (EPS) forecast of -$1.72 for the next financial year.
What is the trend in the Trevena share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Trevena. Over the past six months, its share price has underperformed the S&P500 Index by -41.86%.
As of the last closing price of $0.38, shares in Trevena were trading -43.73% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Trevena PE Ratio?
The Trevena PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.38.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Trevena?
Trevena's management team is headed by:
- Leon Moulder - NEC
- Carrie Bourdow - PRE
- Barry Shin - CFO
- Mark Demitrack - SVP
- Robert Yoder - SVP
- Scott Braunstein - IND
- Michael Dougherty - IND
- Marvin Johnson - IND
- Jake Nunn - IND
- Anne Phillips - IND
- Barbara Yanni - IND